Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Management of nausea and vomiting induced by antibody-drug conjugates.
Breast Cancer
January 2025
Advanced Cancer Translational Research Institute, Showa University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan.
Antibody-drug conjugates (ADCs) are an emerging class of anticancer therapy that combines the specificity and long circulation half-life of monoclonal antibodies with the cytotoxic potency of the payload connected through a chemical linker. The optimal management of toxicities is crucial for improving quality of life in patients undergoing ADCs and for avoiding improper dose reductions or discontinuations. This article focuses on the characteristics and management of nausea and vomiting (NV) induced by three ADCs: trastuzumab deruxtecan (T-DXd), sacituzumab govitecan (SG), and datopotamab deruxtecan (Dato-DXd).
View Article and Find Full Text PDFPerioperative Venous Thromboembolism Prophylaxis in Orthopedic Trauma: A Practical Review.
R I Med J (2013)
February 2025
Division of Trauma and Surgical Critical Care, The Warren Alpert Medical School of Brown University, Rhode Island Hospital, Providence, Rhode Island.
Background: Orthopedic trauma patients are at high risk for venous thromboembolic (VTE) complications. Despite this, VTE prophylaxis is often held peri-operatively out of concern for increased bleeding and associated complications. This review's purpose is to examine guidelines and studies on withholding prophylactic anticoagulation peri-operatively.
View Article and Find Full Text PDFEllagic acid alleviates NLRP6/caspase-1/GSDMD-mediated inflammation and pyroptosis in rats post cerebral ischemia/reperfusion injury.
Iran J Basic Med Sci
January 2025
Department of Pathology, Chongqing Three Gorges Medical College, Wanzhou, China.
Objectives: Ellagic acid (EA) is a natural polyphenol with anti-cancer, anti-oxidant, anti-inflammatory, antibacterial, and other effects. However, the role of EA in cerebral ischemia/reperfusion injury (CIRI) remains unclear. This study aims to investigate the neuroprotective effects of EA in CIRI.
View Article and Find Full Text PDFLBP-CD155 Liposome Nanovaccine Efficiently Resist Colorectal Cancer and Enhance ICB Therapy.
Int J Nanomedicine
January 2025
School of Basic Medicine, Ningxia Medical University, Yinchuan, People's Republic of China.
Background: Colorectal cancer (CRC) is a highly malignant and aggressive gastrointestinal tumor. Due to its weak immunogenicity and limited immune, cell infiltration lead to ineffective clinical outcomes. Therefore, to improve the current prophylaxis and treatment scheme, offering a favorable strategy efficient against CRC is urgently needed.
View Article and Find Full Text PDFImpact of Prophylactic Use of PEG-rhG-CSF on First-Line Immunochemotherapy in Advanced NSCLC: A Cohort Study.
JTO Clin Res Rep
February 2025
Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, People's Republic of China.
Introduction: This study aimed to assess the impact of prophylactic use of PEG-rhG-CSF on first-line immunochemotherapy in advanced NSCLC.
Methods: A cohort of patients with advanced NSCLC who received first-line immunochemotherapy at Shengjing Hospital of China Medical University between January 2019 and July 2024 was selected for this study. Patients were divided into the following two groups: a treatment group that received prophylactic PEG-rhG-CSF (≥1 cycle) 48 hours after immunochemotherapy and a control group that did not receive PEG-rhG-CSF.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!